Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
April 07, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
April 05, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery There are approximately 3-4 million...
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results
March 02, 2022 16:05 ET
|
Verrica Pharmaceuticals Inc.
NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022 Company expects to dose first patient in Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarter of...
Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference
February 24, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum
December 15, 2021 16:05 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
November 29, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
November 18, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each year WEST...
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 12, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA Verrica is engaging with the FDA...
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
September 20, 2021 16:05 ET
|
Verrica Pharmaceuticals Inc.
No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer No Clinical, Safety or CMC Issues Specific to...
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 10, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...